Cancer treatment procedures using radiofrequency ablation will grow at almost 12% in the US over the next five years, according to Millennium Research Group.
Waltham, Massachusetts (PRWEB) December 6, 2007 -- Millennium Research Group forecasts that radiofrequency ablation (RFA) procedures for cancer treatment will grow at almost 12% over the next five years in the US. According to Millennium Research Group's US Markets for Nonvascular Interventional Radiology Devices 2008 report, over 21,000 RFA procedures will be performed in 2007 on patients with liver, kidney, breast, lung, and metastatic bone cancers; by 2012, RFA procedures will reach over 36,000.
Physicians are opting for this surgery due to its minimally invasive nature and its ability to safely and precisely ablate small tumors. If the continued release of clinical evidence supports RFA treatment as a viable alternative to surgical resection, physician confidence in and the subsequent adoption of RFA devices take place.
"RFA can be used in cases where surgical resection poses too great of a risk to the patient," says Stephanie LaBelle, Analyst at MRG. "As a result, RFA increases the treatable patient population."
The US Markets for Nonvascular Interventional Radiology Devices 2008 report includes coverage of many industry competitors, including AngioDynamics, Boston Scientific, and Covidien.
read the full article>> http://www.prweb.com/releases/2007/12/prweb574320.htm
No comments:
Post a Comment